Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19 virus). Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus.

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel COVID-19 virus. Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus. The purpose of this trial is to provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.

Inclusion Criteria:

• Ages 6 and up
• Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants ≥ 18 years of age); or willing and able to provide assent as required per Institutional Review Board (IRB) prior to performing study procedures.
• Must have laboratory confirmed COVID-19 positive test
• Must have severe or immediately life-threatening COVID-19

Severe disease is defined as:

1. dyspnea

2. respiratory frequency ≥ 30/min

3. blood oxygen saturation ≤ 93%

4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or

5. lung infiltrates > 50% within 24 to 48 hours

   Life-threatening disease is defined as:

6. respiratory failure

7. septic shock, and/or

8. multiple organ dysfunction or failure

Exclusion Criteria:

• Known contraindication to transfusion or history of prior reactions to transfusion of blood products